Roche, BC Cancer & CPHIN collaborate to generate real-world evidence

• This collaboration, called Precision Oncology Evidence Development in Cancer Treatment, or PREDiCT, aims to generate and assess real-world evidence, and with this data influence the development of new reimbursement pathways for precision oncology therapies
• Biomarker-informed precision oncology drugs are often indicated for rare subpopulations of cancer patients, making traditional analyses difficult – PREDiCT will encourage greater use of real-world evidence in regulatory and reimbursement decisions

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: JUN2021BR001